UCB (OTCMKTS:UCBJF) Shares Gap Up – Should You Buy?

UCB SA (OTCMKTS:UCBJF) shares gapped up prior to trading on Wednesday . The stock had previously closed at $270.35, but opened at $289.84. UCB shares last traded at $287.4875, with a volume of 424 shares traded.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on UCBJF shares. Wolfe Research started coverage on shares of UCB in a report on Monday, February 23rd. They issued an “outperform” rating on the stock. The Goldman Sachs Group reaffirmed a “buy” rating on shares of UCB in a report on Monday, February 16th. Six investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, UCB has an average rating of “Buy”.

UCB Stock Performance

The business’s fifty day simple moving average is $294.94 and its 200 day simple moving average is $296.12. The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.